Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study
21 Ottobre 2008 - 2:30PM
PR Newswire (US)
EXTON, Pa., Oct. 21 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc.
(AMEX:ILE) announced today that all injections have been completed
in the Phase II/III Study IT-A-008 investigating Isolagen
Therapy(TM) for the treatment of moderate to severe facial acne
scars. Further, approximately half of all of the study participants
have completed the final observation visit. Isolagen anticipates
the acne study will conclude in the first quarter of 2009. "The
second half of 2008 has been very productive for Isolagen as we
continue to deliver on our clinical milestones on time and with
positive results," said Declan Daly, Chief Executive Officer of
Isolagen. "We previously announced positive top-line results from
our pivotal Phase III wrinkle study and positive results from our
open label Phase II study of the full face. We are very excited
that our acne program is progressing on time and we believe the
dermatology community will be very interested in this data early
next year because of the unmet need for a minimally invasive acne
scar treatment. Our current priority is to gain additional funding
and secure a strategic partner to help us deliver on the exciting
clinical promise of the Isolagen therapy in all of these areas."
About the Isolagen Process(TM) and Isolagen Therapy(TM) The
Isolagen Process(TM) is an innovative cellular processing system
which creates a natural, living cell therapy. By multiplying a
patient's own collagen-producing cells or fibroblasts into tens of
millions of new cells, a personalized treatment is created which is
then returned to the patient's skin. This treatment, known as the
Isolagen Therapy(TM), is designed to improve skin damage caused by
the normal effects of aging, sun damage, acne and burns. About
Isolagen, Inc. Isolagen(TM), Inc. (AMEX:ILE) is an aesthetic and
therapeutic company committed to developing and commercializing
scientific advances and innovative technologies. The company's
technology platform includes the Isolagen Process(TM), a cell
processing system for skin and tissue rejuvenation which is
currently in clinical development for a broad range of aesthetic
and therapeutic applications including wrinkles, acne scars, burns
and periodontal disease. Isolagen also commercializes a
scientifically-advanced line of skincare systems through its
majority-owned subsidiary, Agera(R) Laboratories, Inc. For
additional information, please visit http://www.isolagen.com/.
Isolagen Forward Looking Statements All statements in this news
release that are not based on historical fact are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 and the provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
statements in this press release, include, without limitation, the
timely completion of the overall acne study, the timely completion
of the Company's Phase III wrinkle study, and the Company's ability
to raise additional funding, whether through strategic partners,
financing, or otherwise. While management has based any
forward-looking statements contained herein on its current
expectations, the information on which such expectations were based
may change. These forward-looking statements rely on a number of
assumptions concerning future events and are subject to a number of
risks, uncertainties, and other factors, many of which are outside
of our control, that could cause actual results to materially
differ from such statements. Such risks, uncertainties, and other
factors include, but are not necessarily limited to, those set
forth under Item 1A "Risk Factors" in the Company's Annual Report
on Form 10-K for the year ended December 31, 2007, as updated in
"Item 1A. Risk Factors" in the Company's Quarterly Reports on Form
10-Q filed since the annual report. We operate in a highly
competitive and rapidly changing environment, thus new or
unforeseen risks may arise. Accordingly, investors should not place
any reliance on forward-looking statements as a prediction of
actual results. We disclaim any intention to, and undertake no
obligation to, update or revise any forward-looking statements.
Readers are also urged to carefully review and consider the other
various disclosures in the Company's Annual Report on Form 10-K for
the year ended December 31, 2007, as well as other public filings
with the SEC since such date. DATASOURCE: Isolagen, Inc. CONTACT:
Mike Beyer of Sam Brown Inc. for Isolagen, Inc., +1-773-463-4211,
Copyright
Grafico Azioni Isolagen (AMEX:ILE)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Isolagen (AMEX:ILE)
Storico
Da Giu 2023 a Giu 2024